Linked Life Data

20658263

Source:http://linkedlifedata.com/resource/pubmed/id/20658263

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-8-11
pubmed:abstractText
nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant regimen in patients with early stage breast cancer. Patients with node-positive or high-risk node-negative early-stage breast cancer were eligible following completion of standard primary therapy. All the patients received four cycles, at 21-day intervals, of nab-paclitaxel (100 mg/m(2) IV days 1, 8, and 15) and cyclophosphamide (600 mg/m(2) IV day 1). HER2-positive patients also received trastuzumab 8 mg/kg IV on cycle 1 day 1, followed by 6 mg/kg every 21 days for a total of 52 weeks. The purpose of this trial was to evaluate feasibility and toxicity of this nab-paclitaxel-containing adjuvant regimen. 62 patients were treated between 2/08 and 11/08. The majority of the patients (87%) were HER2-negative. This adjuvant regimen was well tolerated, and full doses of all agents were administered in >90% of cycles. Grade 3/4 neutropenia occurred in 53% of the patients; however, only one episode of febrile neutropenia occurred in a total of 249 cycles administered. Other grade 3/4 adverse events occurred in less than 5% of patients. After short follow-up, all the patients remain alive and disease-free. The combination of nab-paclitaxel and cyclophosphamide, with or without trastuzumab, is feasible and well tolerated in patients with early stage breast cancer. Further investigation of the role of nab-paclitaxel in adjuvant breast cancer therapy is indicated, but definitive evaluation will require randomized phase III trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1573-7217
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
123
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
471-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:20658263-Adult, pubmed-meshheading:20658263-Aged, pubmed-meshheading:20658263-Albumins, pubmed-meshheading:20658263-Antibodies, Monoclonal, pubmed-meshheading:20658263-Antibodies, Monoclonal, Humanized, pubmed-meshheading:20658263-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20658263-Breast Neoplasms, pubmed-meshheading:20658263-Chemotherapy, Adjuvant, pubmed-meshheading:20658263-Cyclophosphamide, pubmed-meshheading:20658263-Disease-Free Survival, pubmed-meshheading:20658263-Drug Administration Schedule, pubmed-meshheading:20658263-Feasibility Studies, pubmed-meshheading:20658263-Female, pubmed-meshheading:20658263-Humans, pubmed-meshheading:20658263-Kaplan-Meier Estimate, pubmed-meshheading:20658263-Lymphatic Metastasis, pubmed-meshheading:20658263-Middle Aged, pubmed-meshheading:20658263-Nanoparticles, pubmed-meshheading:20658263-Neoplasm Staging, pubmed-meshheading:20658263-Paclitaxel, pubmed-meshheading:20658263-Pilot Projects, pubmed-meshheading:20658263-Receptor, erbB-2, pubmed-meshheading:20658263-Time Factors, pubmed-meshheading:20658263-Treatment Outcome, pubmed-meshheading:20658263-United States
pubmed:year
2010
pubmed:articleTitle
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
pubmed:affiliation
Sarah Cannon Research Institute, 3322 West End Avenue Suite 900, Nashville, TN 37203, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II